Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment.

Abstract

Hot flushes are the commonest symptom induced by gonadotropin-releasing hormone agonists (GnRHa). We performed an open observational trial to evaluate the efficacy of veralipride, an antidopaminergic drug, in reducing hot flushes in 25 premenopausal women treated with a GnRHa for endometriosis (8 subjects) or menorrhagia (17 subjects). The patients received goserelin depot for 6 months and veralipride was added for the third month. Hot flushes, severe in all women at 2 months, improved in both frequency and intensity in 92% of the subjects during veralipride administration. The benefit obtained persisted until the end of the GnRHa treatment.

• Authors: P Vercellini, N Vendola, A Colombo, C Passadore, L Trespidi, P G Crosignani
• Journal: Gynecologic and obstetric investigation (Gynecol Obstet Invest) Vol. 34 Issue 2 Pg. 102-4 ( 1992) ISSN: 0378-7346 [Print] Switzerland
• PMID: 1398260 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Goserelin
• Estradiol
• Sulpiride
• Prolactin
• Luteinizing Hormone
• Follicle Stimulating Hormone
• veralipride

Topics

• Adult
• Drug Therapy, Combination
• Endometriosis (blood, drug therapy)
• Estradiol (blood)
• Female
• Flushing (chemically induced, classification, drug therapy)
• Follicle Stimulating Hormone (blood)
• Goserelin (adverse effects)
• Humans
• Luteinizing Hormone (blood)
• Menorrhagia (blood, drug therapy)
• Middle Aged
• Prolactin (blood)
• Sulpiride (administration & dosage, analogs & derivatives, therapeutic use)